Join NIAID's Online Meeting on Allergy and Infection Research Funding
Published Date: 4/30/2025
Notice
Summary
The National Institute of Allergy and Infectious Diseases is holding a virtual meeting on June 2, 2025, to review grant applications and share important updates. Scientists, researchers, and grant applicants should pay attention because decisions made here could affect funding and research projects. The meeting is partly open to the public and free to watch online, making it easy to stay in the loop!
Analyzed Economic Effects
4 provisions identified: 3 benefits, 0 costs, 1 mixed.
Grant Reviews Could Affect Funding
If you are a scientist, researcher, or grant applicant, the National Advisory Allergy and Infectious Diseases Council will review and evaluate grant applications on June 2, 2025. Decisions made at that review could affect whether projects receive NIH funding and the future of those research projects.
Public Can Watch Meeting Online
The meeting on June 2, 2025 will be open to the public and open sessions will be videocast on the NIH Videocasting and Podcasting website (http://videocast.nih.gov). Open session times listed include 10:30 a.m. to 11:45 a.m. and 1:00 p.m. to 4:30 p.m.
Closed Sessions Protect Confidential Information
Parts of the June 2, 2025 meeting will be closed (for example 8:30 a.m. to 10:00 a.m. and 11:45 a.m. to 12:00 p.m.) because discussions may disclose confidential trade secrets, patentable material, or personal information associated with grant applications. Those closed sessions are being withheld under provisions of Title 5 U.S.C. (sections 552b(c)(4) and 552b(c)(6)).
Anyone May Submit Written Comments
Any interested person may file written comments with the committee by forwarding a statement to the Contact Person listed (Kelly Y. Poe, Ph.D., Director, Division of Extramural Activities) and should include name, address, telephone number, and when applicable, business or professional affiliation.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16683, Proposed Collection; 60-Day Comment Request; Data Use Certification for the NIH National Institute on Drug Abuse Data Share Site
The purpose of this notice is to inform the public of the information collection requirement for the NIDA Data Share, the data use terms and conditions, and to request a progress report statement at the time of renewal. In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-16544, Government-Owned Inventions; Availability for Licensing
The inventions listed below are owned by an agency of the U.S. Government and are available for licensing to achieve expeditious commercialization of results of federally-funded research for the benefit of the public health.
2026-16440, NIH Owned Invention Available for License: Soluble Tissue Factor, a Novel Target, and Antibodies, for Diagnosis, Prevention and Treatment of Thrombosis and Related Conditions
Scientists at the National Cancer Institute (NCI) have discovered a novel therapeutic, diagnostic and prognostic target for thrombosis: Soluble Tissue Factor (sTF). NCI has generated first-in- class antibodies and platform selectively neutralizing pathological coagulation while preserving normal hemostasis. This platform technology can be used to prevent, diagnose and treat pathological thrombosis caused by a variety of clinical conditions-including cancer, sepsis, infectious diseases (e.g., COVID), autoimmune disorders, trauma, heart conditions and inflammatory conditions. It offers a much more sensitive and specific test of thrombosis than the current D-dimer test. It may be applicable to any clinical condition which induces necroptosis, pyroptosis and NETtosis, such as cancer, neurodegenerative disease, ischemia-reperfusion and acute injuries, traumatic injuries, bacterial and viral infections, cardiovascular conditions, and atherosclerosis, inflammatory, autoimmune conditions, and others.
2026-16071, Proposed Collection; 60-Day Comment Request: The Impact of Clinical Research Training and Medical Education at the Clinical Center on Physician Careers in Academia and Clinical Research (Clinical Center)
In compliance with the requirement of the Paperwork Reduction Act of 1995, for opportunity for public comment on proposed data collection projects, the Clinical Center, the National Institutes of Health (NIH) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-15565, Proposed Collection; 60-Day Comment Request, Data Use Certification for the NIH Brain Development Cohorts (NBDC) Data Hub, (National Institute on Drug Abuse)
In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval. The purpose of this revision is to update instructions for the Research Data Use Statement and the Progress Report, and to add new instructions for attesting to National Institute of Standards & Technology (NIST) security compliance, and for a Project Close-out at the time of project completion. Burden levels remain unchanged.
2026-14966, Government-Owned Inventions; Availability for Licensing
The National Institutes of Health is offering a new Ebola vaccine invention for companies to license and develop quickly. This vaccine targets the Bundibugyo virus and promises fast and lasting protection, helping stop outbreaks in Central Africa. Businesses interested in licensing should act soon to bring this life-saving tech to market and can contact NIH for details.
Previous / Next Documents
Previous: 2025-07466, National Human Genome Research Institute; Amended Notice of Meeting
The National Human Genome Research Institute moved its important advisory meeting from April 25 to June 18-19, 2025. This change affects researchers and stakeholders who follow genome science updates. The meeting will still be private, with no public access, but the new dates give everyone more time to prepare.
Next: 2025-07471, Notice of Suspension and Commencement of Proposed Debarment Proceedings; Schools and Libraries Universal Service Support Mechanism
Susan Klein is suspended from the E-Rate Program, which helps schools and libraries get affordable internet. The government is starting a process to possibly ban her from these programs for good. Anyone working with her can speak up by a certain deadline, so watch your calendar and paperwork!